Our Company
Our Mission & Commitment
Key Facts
Leadership
Governance
History
Compliance & Ethics
Diversity & Inclusion
Our Websites
Achievements
Business Information
R&D
R&D Strategy
In the Pipeline
Investigational Compound News
Disease Areas of Focus
Our R&D
Our Science
R&D Highlights
Major R&D Facilities
Clinical Trials
Products
Patient Assistance Programs
Prescribing Information
R&D
Clinical Trials
Counterfeit Drugs
Product Information Inquiries
News
Press Releases
Publications
Media Library
Key Facts
Leadership
Financial Reporting
Features
Achievements
Media Contacts
Subscribe to e-mail alerts
Investors
Key Facts
Stock Information
SEC Filings
Financial Reporting
Events & Presentations
Shareholder Services
Investor Contacts
Partnering
Why Partner With Us?
Areas of Interest
Our Process
Our Partners
Partnering News
Partnering Contact
Responsibility
Bristol-Myers Squibb Foundation
Sustainability
Patient Assistance Programs
Building Our Communities
Grants & Giving
Position on Key Issues
Clinical Trials
Combating Counterfeit Drugs
Achievements
Careers
Job Opportunities
Our Culture
Diversity & Inclusion
Developing Our People
University Recruitment
Achievements
Benefits
Manage My Profile
Apply Now
SITE INDEX
|
CONTACT US
|
TERMS
|
PRIVACY
July 2010
Statement on BMS
HIV/AIDS Access Programs
for Least Developed Countries
Statement on HIV/AIDS
Medicine Access in the U.S.
Statement on
VIDEX® (didanosine) Supply
July 12, 2010
COUMADIN® (warfarin sodium)
1 mg Blister Packs
Recall Information
Health Care Professionals
Access
medical information and resources
Clinical Trials
Clinical trials
sponsored by Bristol-Myers Squibb
Bristol-Myers Squibb
clinical trials for cancer
Need Help Paying for Your Bristol-Myers Squibb Medicines?
Learn about our
assistance programs
.
Our Environmental
Stewardship
Bristol-Myers Squibb Foundation:
Supporting Innovations in Mental Health
Project seeks to lower recidivism in people with
serious mental illness
.
LATEST NEWS
July 22, 2010
Bristol-Myers Squibb National Survey Finds a Disparity Between Health Care Providers and HIV Positive Patients Perspectives on the Emotional Barriers to Seeking HIV Care and Treatment
July 22, 2010
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
July 13, 2010
Bristol-Myers Squibb to Announce Results for Second Quarter 2010 on July 22
July 9, 2010
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Get RSS News Alerts
Follow us on twitter.com/bmsnews